ENSO
San Francisco
About ENSO
1.5 billion people worldwide live with chronic pain, and the best option they have are drugs like Vicodin that have terrible side effects and make people feel sick. ENSO has developed the first opioid-free, wearable device clinically proven to solve pain better than Vicodin. It works by delivering a patented electrical stimulation treatment that relaxes the muscles and calms the nerves wherever it is applied, and it's all controlled via an app on your smartphone. Enso is being used to solve chronic and acute pain at over 100 medical centers in the US such as Stanford, Harvard and Cedars-Sinai. The device is covered by the VA Hospitals and workers compensation insurance plans and is expected to be covered by major commercial insurance plans by 2021.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.5M
- Funding stage: M&A
- Last round: Series A (Apr 2017)
- Website: ensorelief.com
- Phone: [email protected]
Industries & Categories
Consumer, Medical Device, Wearables, Wellness
Social Profiles
Canonical: https://fsome.com/organization/enso-141501 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.